Article PDF first page preview

First page of Gut microbiome composition and one-year survival outcomes among patients with reduced ejection fraction heart failure

Background: Imbalances in gut microbiota are linked to chronic diseases, including heart failure, where shifts in microbial composition are evident in patients with reduced ejection fraction (HFrEF). This study compared gut microbiome profiles between HFrEF patients and healthy controls and explored potential links between microbiome composition and patient survival over 6 and 12 months. Methods: In this longitudinal case-control study, 20 HFrEF patients and 40 healthy controls were recruited, with stool samples collected for gut microbiome analysis. Patients were followed for six and twelve months to assess survival. Gut microbiome composition was analyzed using real-time PCR for specific bacterial taxa. Statistical analyses were performed using R to compare HFrEF and control groups and draw the ROC curve to predict survival at six and twelve months. Results: HFrEF patients showed a significantly lower abundance of all bacterial taxa, except for A. muciniphila. Decreased levels of Prevotella, F. prausnitzii, Firmicutes, and Bacteroides, as well as a lower Firmicutes/Bacteroidetes (F/B) ratio, were notable in HFrEF patients, with specific taxa correlating with clinical features like ascites and vitamin D levels. Most bacterial taxa and the F/B ratio could distinguish HFrEF patients from controls, though none effectively predicted survival outcomes at six or twelve months. Conclusion: The study demonstrates that patients with HFrEF exhibit a distinct gut microbiome profile compared to healthy individuals. While specific gut bacteria were effective in distinguishing HFrEF patients from healthy controls, their ability to predict survival outcomes was limited, highlighting the need for further research into the role of the gut microbiome in the progression and prognosis of heart failure.

Journal Section:
HF and Intensive Care
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.